Predicting MRI Abnormalities With Longitudinal Data of the Whitehall II Substudy

Sponsor
University of Oxford (Other)
Overall Status
Completed
CT.gov ID
NCT03335696
Collaborator
University College, London (Other)
800
1
65.9
12.1

Study Details

Study Description

Brief Summary

Follow-up study within the Whitehall II study, selecting 800 participants for further neuropsychological, clinical and imaging (MRI) examinations to examine brain structure and function in relation to age-related diseases and the modifiable and non-modifiable factors affecting resilience against and vulnerability to adverse brain changes.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    A total of 6035 civil servants participated in the WHII Phase 11 clinical examination in 2012-2013. A random sample of 800 of these participants was included in a sub-study comprising an MRI brain scan, a detailed clinical and cognitive assessment, and collection of blood and buccal mucosal samples for the characterisation of immune function and associated measures. Data collection for this sub-study started in 2012 and was completed by in 2016. The participants, for whom social and health records have been collected since 1985, were between 60-85 years of age at the time the MRI study started. The pre-specified clinical and cognitive assessment protocols, the state-of-the-art MRI sequences and latest pipelines for analyses of this sub-study have been published and are attached to this application.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    800 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Predicting MRI Abnormalities With Longitudinal Data of the Whitehall II Substudy
    Actual Study Start Date :
    Jan 1, 2012
    Actual Primary Completion Date :
    Jun 30, 2017
    Actual Study Completion Date :
    Jun 30, 2017

    Outcome Measures

    Primary Outcome Measures

    1. Neuropsychological measure 1 [2012-2016]

      National Adult Reading Test (premorbid intellectual ability)

    2. Neuropsychological measure 2 [2012-2016]

      Montreal Cognitive Assessment (MoCA)

    3. Neuropsychological measure 3 [2012-2016]

      Rey Complex Figure copy and delayed recall (visual episodic memory)

    4. Neuropsychological measure 4 [2012-2016]

      Hopkins Verbal Learning Test Revised (verbal episodic memory)

    5. Neuropsychological measure 5 [2012-2016]

      CANTAB Simple and Choice Reaction Time (processing speed)

    6. Neuropsychological measure 6 [2012-2016]

      WAIS-R Digit Symbol Test (processing speed)

    7. Neuropsychological measure 7 [2012-2016]

      Trail Making Test A and B (processing speed/executive functioning)

    8. Neuropsychological measure 8 [2012-2016]

      WAIS-R Digit Span forward and backwards (executive functioning)

    9. Neuropsychological measure 9 [2012-2016]

      Graded Naming Test (semantic memory)

    10. MRI Measures 1 [2012-2016]

      Siemens 3T - T1-weighted scan (MPRAGE) using FSL FIRST, FAST, and Freesurfer Volume extractions

    11. MRI Measures 2 [2012-2016]

      Siemens 3T - T1-weighted scan (MPRAGE) using FSL GLM Voxel based analysis for grey matter density analysis

    12. MRI Measures 3 [2012-2016]

      Siemens 3T - T2-weighted scan, clinical and FSL (BIANCA)-based rating of white matter changes

    13. MRI Measures 4 [2012-2016]

      Siemens 3T Diffusion Tensor Images analyzed with Tract Based Spatial Statistics (TBSS)

    14. MRI Measures 5 [2012-2016]

      Siemens 3T rs-fMRI analyzed with Multivariate Exploratory Linear Optimized Decomposition into Independent Components: MELODIC)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Member of Whitehall II cohort attending at UCL for phase 11
    Exclusion Criteria:
    • Not suitable for MRI, travelling to Oxford, seriously physically ill

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Oxford Oxford England United Kingdom OX3 7JX

    Sponsors and Collaborators

    • University of Oxford
    • University College, London

    Investigators

    • Principal Investigator: Klaus P Ebmeier, MD, University of Oxford

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    University of Oxford
    ClinicalTrials.gov Identifier:
    NCT03335696
    Other Study ID Numbers:
    • MSD/IDREC/C1/2011/71
    First Posted:
    Nov 8, 2017
    Last Update Posted:
    Nov 8, 2017
    Last Verified:
    Nov 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of Oxford
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 8, 2017